



Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still ' s disease

| | |
|------------------------------|---|
| 著者 | Asano Tomoyuki, Furukawa Hiroshi, Sato Shuzo, Yashiro Makiko, Kobayashi Hiroko, Watanabe Hiroshi, Suzuki Eiji, Ito Tomoyuki, Ubara Yoshifumi, Kobayashi Daisuke, Iwanaga Nozomi, Izumi Yasumori, Fujikawa Keita, Yamasaki Satoshi, Nakamura Tadashi, Koga Tomohiro, Shimizu Toshimasa, Umeda Masataka, Nonaka Fumiaki, Yasunami Michio, Ueki Yukitaka, Eguchi Katsumi, Tsuchiya Naoyuki, Tohma Shigeto, Yoshiura Koh-ichiro, Ohira Hiromasa, Kawakami Atsushi, Migita Kiyoshi |
| journal or publication title | Arthritis research & therapy |
| volume | 19 |
| number | 1 |
| page range | 199 |
| year | 2017-09 |
| 権利 | (C) The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| URL | http://hdl.handle.net/2241/00150885 |

doi: 10.1186/s13075-017-1406-x

Creative Commons : 表示

<http://creativecommons.org/licenses/by/3.0/deed.ja>

RESEARCH ARTICLE

Open Access



Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease

Tomoyuki Asano¹, Hiroshi Furukawa², Shuzo Sato¹, Makiko Yashiro¹, Hiroko Kobayashi¹, Hiroshi Watanabe¹, Eiji Suzuki³, Tomoyuki Ito⁴, Yoshifumi Ubara⁵, Daisuke Kobayashi⁶, Nozomi Iwanaga⁷, Yasumori Izumi⁷, Keita Fujikawa⁸, Satoshi Yamasaki⁹, Tadashi Nakamura¹⁰, Tomohiro Koga¹¹, Toshimasa Shimizu¹¹, Masataka Umeda¹¹, Fumiaki Nonaka¹², Michio Yasunami¹³, Yukitaka Ueki¹⁴, Katsumi Eguchi¹⁴, Naoyuki Tsuchiya², Shigeto Tohma¹⁵, Koh-ichiro Yoshiura¹⁶, Hiromasa Ohira¹⁷, Atsushi Kawakami¹¹ and Kiyoshi Migita^{1*}

Abstract

Background: *HLA-DRB1* alleles are major determinants of genetic predisposition to rheumatic diseases. We assessed whether *DRB1* alleles are associated with susceptibility to particular clinical features of adult onset Still's disease (AOSD) in a Japanese population by determining the *DRB1* allele distributions.

Methods: *DRB1* genotyping of 96 patients with AOSD and 1,026 healthy controls was performed. Genomic DNA samples from the AOSD patients were also genotyped for *MEFV* exons 1, 2, 3, and 10 by direct sequencing.

Results: In Japanese patients with AOSD, we observed a predisposing association of *DRB1*15:01* ($p = 8.60 \times 10^{-6}$, corrected p (P_c) = 0.0002, odds ratio (OR) = 3.04, 95% confidence interval (95% CI) = 1.91–4.84) and DR5 serological group ($p = 0.0006$, OR = 2.39, 95% CI = 1.49–3.83) and a protective association of *DRB1*09:01* ($p = 0.0004$, $P_c = 0.0110$, OR = 0.34, 95% CI = 0.18–0.66) with AOSD, and amino acid residues 86 and 98 of the DR β chain were protectively associated with AOSD. *MEFV* variants were identified in 49 patients with AOSD (56.3%). The predisposing effect of DR5 was confirmed only in patients with AOSD who had *MEFV* variants and not in those without *MEFV* variants. Additionally, DR5 in patients with AOSD are associated with macrophage activation syndrome (MAS) and steroid pulse therapy.

Conclusion: The *DRB1*15:01* and DR5 are both associated with AOSD susceptibility in Japanese subjects. A protective association between the *DRB1*09:01* allele and AOSD was also observed in these patients. Our data also highlight the effects of *DRB1* alleles in susceptibility to AOSD.

Keywords: Adult onset Still's disease, Autoinflammatory disease, Human leukocyte antigen, Macrophage-activation syndrome, Systemic juvenile idiopathic arthritis

Background

Adult onset Still's disease (AOSD), manifested by spiking fever, skin rash, and arthritis, is a complex (multigenic) autoinflammatory disease, meaning that its development depends on a combination of genetic and environmental risk factors [1]. The concept of autoinflammation originally emerged from innate immune system activation

[2]. Although there are rare monogenic forms of autoinflammatory disease, acquired autoinflammatory diseases in which both innate and adaptive immune abnormalities are implicated are more common [3]; this group includes genetically complex rheumatic diseases, such as AOSD [4]. Complex genetic factors may confer susceptibility to AOSD development under certain environmental conditions [5].

The *HLA* cluster is one of the most intensively studied genetic factors in AOSD [6]. *HLA* molecules are linked with adaptive immunity, where they act to present

* Correspondence: migita@fmu.ac.jp

¹Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan
Full list of author information is available at the end of the article

peptide antigens to antigen receptors on T lymphocytes [7]. Currently, there is no consensus on the relationship between AOSD and *HLA*. Previous studies on the genetic predisposition to AOSD have limitations and have had inconsistent results [8]. This may be caused by the small number of patients included in these studies, due to the rarity of this disease and its heterogeneous clinical manifestations.

Systemic juvenile idiopathic arthritis (sJIA) and AOSD both manifest as systemic arthritis [9]. Recent studies have provided new clues to the genetic underpinning of sJIA. A genome-wide association study of sJIA identified a strong association between sJIA and *HLA-DRB1*11* [10]. This study supports a role for *DRB1* alleles as a major sJIA risk factor [10]. To determine whether or not genetic variations of *DRB1* alleles also influence AOSD risk, we investigated the *DRB1* alleles in Japanese patients with AOSD. Previously, we found preliminary evidence suggesting that familial Mediterranean fever (FMF)-related *MEFV* variants can affect the disease phenotype of AOSD [11]. In this study we evaluated the influence of the *MEFV* genotype and *HLA-DRB1* alleles on AOSD risk.

Methods

Design, setting, patients, and measurements

We retrospectively evaluated 96 patients (mean age \pm standard deviation = 50.2 ± 20.2 years, 78 female (81.2%)), who had AOSD and were treated at the Department of Rheumatology of the participating hospital group, between 2010 and 2017. The patients had all been diagnosed with AOSD according to the Yamaguchi criteria [12], after exclusion of infectious, hematologic, and autoimmune diseases. Among 96 patients, 87 patients had undergone laboratory tests, including a complete blood count, liver function tests, urinalysis, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and ferritin. In the remaining nine patients, the demographic and *MEFV* genotyping data were not available except gender and age. The clinical characteristics of these patients, including age, gender, length of follow up, clinical features, treatments, outcomes, and complications, were evaluated using a standardized form. The study considered three clinical AOSD courses: (1) monocyclic, defined as a single episode that subsequently faded and was followed by persistent good health for 1 year or more of follow up; (2) polycyclic, defined as a complete remission followed by one or more exacerbations; and (3) chronic, defined as persistently active disease, usually associated with polyarthritis [13]. Complicated AOSD was defined as including one or more of the following conditions: liver dysfunction, disseminated intravascular coagulation, and macrophage activation syndrome (MAS) as defined previously [14]. This

study was approved by the institutional review board of the Sasebo City Hospital (number 2012-A-22) and participating hospitals.

Genotyping methods

DRB1 allele typing was performed using a Luminex 200 system (Luminex, Austin, TX, USA) and a WAK-Flow HLA Typing kit (Wakunaga, Hiroshima, Japan) as described previously [15]. *DRB1* alleles were assigned automatically using WAKflow Typing software (Wakunaga). The DR5 serological group consists of *DRB1*11:01*, **12:01*, and **12:02* [16]. Genotyping results for the healthy controls (mean age \pm standard deviation = 37.7 ± 11.7 years, 303 male (29.8%)) were previously reported [17].

MEFV gene analysis

Genomic DNA was extracted from whole blood using the Promega Wizard[®] Genomic DNA Purification Kit (Madison, WI, USA) according to the manufacturer's instructions. Polymerase chain reaction (PCR) was performed using forward and reverse primers for each exon of the *MEFV* gene, as described previously [18]. PCR was performed using the forward and reverse primers for each exon (Additional file 1: Figure S1). The resulting PCR products were purified using ExoSAP-IT (GE Healthcare, Tokyo, Japan) and directly sequenced using specific primers and BigDye Terminator v1.1 (Applied Biosystems, Tokyo, Japan). The *MEFV* genetic analysis was approved by the Ethics Committee of Fukushima Medical University School of Medicine (2016, number 2920).

Statistical analysis

Differences among AOSD characteristics were analyzed by performing the Mann-Whitney *U* test or chi-squared test using 2×2 contingency tables. The association of allele carrier frequencies, haplotype carrier frequencies or amino acid residue carrier frequencies with AOSD was analyzed using Fisher's exact test with 2×2 contingency tables under the dominant model. Adjustment for multiple comparisons was conducted with the Bonferroni method; corrected *p* (*P_c*) values were calculated by multiplying the *p* value by the number of tested alleles or amino acid positions. To examine whether each *DRB1* allele independently contributes to AOSD, multiple logistic regression analysis under the additive model was employed and the deviation from 0 was evaluated for coefficients using the Wald test.

Results

Demographic findings of enrolled patients with AOSD

Clinical manifestations of the enrolled patients are shown in Table 1. Among the 87 enrolled patients

Table 1 Demographics of AOSD patients

| Variable | Value |
|--|-------------------|
| Number | 87 |
| Female, <i>n</i> (%) | 69 (79.3) |
| Age at onset (years) | 49.3 ± 19.9 |
| Ferritin (ng/mL) | 11251.2 ± 16997.9 |
| CRP (mg/dL) | 12.4 ± 8.2 |
| ESR (mm(1 h)) | 71.1 ± 30.1 |
| Liver dysfunction, <i>n</i> (%) | 68 (78.1) |
| MAS, <i>n</i> (%) | 23 (26.4) |
| Initial dose of PSL (mg/day) | 41.8 ± 12.2 |
| Steroid pulse, <i>n</i> (%) | 55 (63.2) |
| Immunosuppressant, <i>n</i> (%) | 51 (58.6) |
| Biologics, <i>n</i> (%) | 26 (29.8) |
| Polycyclic systemic type, <i>n</i> (%) | 56 (64.3) |
| Monocyclic systemic type, <i>n</i> (%) | 19 (21.8) |
| Chronic arthritis type, <i>n</i> (%) | 12 (13.7) |
| Relapse, <i>n</i> (%) | 40 (45.9) |

Mean ± standard deviation or number (percentage) is shown
 AOSD adult onset Still's disease, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MAS macrophage activation syndrome, PSL prednisolone

with AOSD, 69 (79.3%) were women, and the mean age at diagnosis was 49.3 ± 19.9 years. In terms of the disease course, 56 patients (64.3%) had the polycyclic systemic type, 19 (21.8%) had the monocyclic systemic type, and 12 (13.7%) had the chronic articular type of AOSD (Table 1).

Association of specific *DRB1* alleles with AOSD

Associations of specific *DRB1* alleles with AOSD were evaluated in a case-control study consisting of the 96 Japanese patients with AOSD as described previously and 1026 healthy subjects (Table 2). The patients with AOSD had significantly higher frequencies of the *DRB1*15:01* allele ($p = 8.60 \times 10^{-6}$, corrected p (P_c) = 0.0002, odds ratio (OR) = 3.04, 95% confidence interval (95% CI) = 1.91–4.84) compared with healthy subjects. Although patients with AOSD appeared to have higher frequencies of *DRB1*12:01* allele than healthy subjects, this difference was not statistically significant. However, an association between DR5 serological group and AOSD was observed.

Reduced *DRB1*09:01* allele carrier frequencies in AOSD

In contrast to the predisposing effects of the *DRB1*15:01* allele, *DRB1*09:01* was negatively associated with AOSD (Table 2). In fact, although the *DRB1*15:01* allele predisposed individuals to AOSD in the absence of *DRB1*09:01*, the *DRB1*15:01* allele was not associated with AOSD in those carrying the *DRB1*09:01* allele (Table 3). Thus, the protective effects of *DRB1*09:01*

can neutralize the AOSD-predisposing effects of the *DRB1*15:01* allele. When the allele carrier frequencies of *DRB1* alleles in patients with AOSD were compared with age-matched healthy controls, a similar associative tendency was observed (Additional file 2: Table S1). In addition, conditional logistic regression analysis between age, gender, *DRB1*09:01*, *DRB1*15:01*, and DR5 in AOSD was performed (Additional file 3: Table S2). The association of *DRB1*09:01*, *DRB1*15:01*, and DR5 remained significant, when conditioned on age or gender, and these were independent of each other.

MEFV variant analysis

All patients with AOSD were successfully genotyped for the *MEFV* gene. *MEFV* variants were identified in 49 patients with AOSD (56.3%), and the distributions of *MEFV* variants in the patients are shown in Table 4. We stratified the patients with AOSD according to the presence of *MEFV* variants. The predisposing effect of *DRB1*15:01* on AOSD development was not changed by the presence or absence of *MEFV* variants (Table 5). In contrast, the AOSD-predisposing effect of DR5 was confirmed in patients with AOSD with *MEFV* variants, but DR5 was not associated with AOSD in patients without *MEFV* variants. Thus, the presence or absence of *MEFV* variants can affect the AOSD-predisposing effects of DR5.

Association of specific *DRB1* alleles and clinical manifestations of AOSD

To evaluate the potential correlation between *DRB1* alleles and the clinical manifestations of AOSD, we stratified the patients with AOSD according to the presence of the *DRB1*15:01* allele (Table 6). There was no significant difference in the clinical manifestations, including the disease phenotype, between patients with AOSD with and without the *DRB1*15:01* allele. We then compared the clinical manifestations between patients with AOSD with or without DR5. Patients with AOSD with DR5 more frequently have macrophage activation syndrome (MAS) and are more frequently treated by steroid pulse therapy than those without DR5 (Table 6).

Amino acid residues in the HLA-DR β chain are protectively associated with AOSD

We also analyzed the association between amino acid residues in the HLA-DR β chain and AOSD. Glycine at position 86 (86G, $p = 7.88 \times 10^{-7}$, OR = 0.24, $P_c = 2.68 \times 10^{-5}$, 95% CI 0.15–0.41) and glutamic acid at position 98 (98E, $p = 2.80 \times 10^{-5}$, OR = 0.40, $P_c = 0.0010$, 95% CI 0.26–0.62) in the DR β chain showed a protective association with AOSD (Fig. 1, open circle).

Table 2 HLA-DRB1 allele carrier frequency in the patients with AOSD and in controls

| | Cases (n = 96) | Controls (n = 1026) | P | OR | P _c | 95% CI |
|---------------|----------------|---------------------|-----------------------|------|----------------|--------------|
| DRB1*01:01 | 9 (9.4) | 110 (10.7) | 0.8622 | 0.86 | NS | (0.42–1.76) |
| DRB1*03:01 | 0 (0.0) | 3 (0.3) | 1.0000 | 1.52 | NS | (0.08–29.55) |
| DRB1*04:01 | 0 (0.0) | 22 (2.1) | 0.2486 | 0.23 | NS | (0.01–3.84) |
| DRB1*04:03 | 4 (4.2) | 47 (4.6) | 1.0000 | 0.91 | NS | (0.32–2.57) |
| DRB1*04:04 | 0 (0.0) | 4 (0.4) | 1.0000 | 1.18 | NS | (0.06–22.03) |
| DRB1*04:05 | 21 (21.9) | 243 (23.7) | 0.8014 | 0.90 | NS | (0.54–1.49) |
| DRB1*04:06 | 2 (2.1) | 76 (7.4) | 0.0562 | 0.27 | NS | (0.06–1.10) |
| DRB1*04:07 | 0 (0.0) | 15 (1.5) | 0.6313 | 0.34 | NS | (0.02–5.70) |
| DRB1*04:10 | 4 (4.2) | 32 (3.1) | 0.5413 | 1.35 | NS | (0.47–3.90) |
| DRB1*07:01 | 0 (0.0) | 9 (0.9) | 1.0000 | 0.55 | NS | (0.03–9.61) |
| DRB1*08:02 | 13 (13.5) | 72 (7.0) | 0.0403 | 2.08 | NS | (1.10–3.90) |
| DRB1*08:03 | 16 (16.7) | 153 (14.9) | 0.6544 | 1.14 | NS | (0.65–2.01) |
| DRB1*08:09 | 0 (0.0) | 2 (0.2) | 1.0000 | 2.12 | NS | (0.10–44.55) |
| DRB1*09:01 | 11 (11.5) | 280 (27.3) | 0.0004 | 0.34 | 0.0110 | (0.18–0.66) |
| DRB1*10:01 | 0 (0.0) | 5 (0.5) | 1.0000 | 0.96 | NS | (0.05–17.54) |
| DRB1*11:01 | 6 (6.3) | 41 (4.0) | 0.2837 | 1.60 | NS | (0.66–3.87) |
| DRB1*12:01 | 16 (16.7) | 75 (7.3) | 0.0031 | 2.54 | 0.0896 | (1.41–4.56) |
| DRB1*12:02 | 8 (8.3) | 37 (3.6) | 0.0488 | 2.43 | NS | (1.10–5.38) |
| DRB1*13:01 | 2 (2.1) | 8 (0.8) | 0.2082 | 2.71 | NS | (0.57–12.93) |
| DRB1*13:02 | 5 (5.2) | 163 (15.9) | 0.0040 | 0.29 | 0.1150 | (0.12–0.73) |
| DRB1*14:03 | 7 (7.3) | 44 (4.3) | 0.1941 | 1.76 | NS | (0.77–4.01) |
| DRB1*14:04 | 0 (0.0) | 4 (0.4) | 1.0000 | 1.18 | NS | (0.06–22.03) |
| DRB1*14:05 | 6 (6.3) | 40 (3.9) | 0.2758 | 1.64 | NS | (0.68–3.98) |
| DRB1*14:06 | 2 (2.1) | 29 (2.8) | 1.0000 | 0.73 | NS | (0.17–3.11) |
| DRB1*14:07 | 0 (0.0) | 2 (0.2) | 1.0000 | 2.12 | NS | (0.10–44.55) |
| DRB1*14:54 | 6 (6.3) | 58 (5.7) | 0.8168 | 1.11 | NS | (0.47–2.65) |
| DRB1*15:01 | 31 (32.3) | 139 (13.5) | 8.60×10^{-6} | 3.04 | 0.0002 | (1.91–4.84) |
| DRB1*15:02 | 18 (18.8) | 224 (21.8) | 0.5197 | 0.83 | NS | (0.48–1.41) |
| DRB1*16:02 | 0 (0.0) | 18 (1.8) | 0.3919 | 0.28 | NS | (0.02–4.72) |
| DR5(*11, *12) | 28 (29.2) | 151 (14.7) | 0.0006 | 2.39 | | (1.49–3.83) |

Allele carrier frequencies are shown in parentheses (%). Association was tested by Fisher's exact test using 2×2 contingency tables under the dominant model. AOSD adult onset Still's disease, OR odds ratio, CI confidence interval, P_c corrected p value, NS not significant

Discussion

AOSD is an inflammatory disorder of uncertain etiology characterized by spiking fever, rash, and arthritis that is accompanied by high ferritin levels [19]. Both sJIA and AOSD are considered to be autoinflammatory diseases

with a dysregulated innate immune system [20]. However, this characterization is limited by the fact that dysfunctions of the innate and adaptive immune systems are not mutually exclusive, even in monogenic forms of autoinflammatory disease [21].

Table 3 HLA-DRB1 genotype frequencies in the patients with AOSD and in controls

| | Cases (n = 96) | Controls (n = 1026) | P | OR | 95% CI |
|----------------------------------|----------------|---------------------|-----------------------|------|-------------|
| *15:01/any alleles | 31 (32.3) | 139 (13.5) | 8.60×10^{-6} | 3.04 | (1.91–4.84) |
| *15:01/*09:01 | 1 (1.0) | 21 (2.0) | 1.0000 | 0.50 | |
| *15:01/alleles other than *09:01 | 30 (31.3) | 118 (11.5) | 1.64×10^{-6} | 3.50 | (2.18–5.61) |

Genotype frequencies are shown in parentheses (%). Association was tested by Fisher's exact test using 2×2 contingency tables. AOSD adult onset Still's disease, OR odds ratio, CI confidence interval

Table 4 *MEFV* genotypes of patients with AOSD

| Mutations | Number of patients (percentage) (n = 87) |
|-------------------------------|--|
| M694I/normal | 2 (2.3) |
| G632S/E408Q | 1 (1.1) |
| P369S/R408Q | 4 (4.6) |
| E148Q/P369S | 1 (1.1) |
| E148Q/E148Q/P369S/R408Q | 1 (1.1) |
| L110P/E148Q/E148Q/P369S/R408Q | 1 (1.1) |
| E148Q/P369S/R408Q | 2 (2.3) |
| E148Q/R202Q | 1 (1.1) |
| R202Q/normal | 3 (3.4) |
| E148Q/normal | 19 (21.8) |
| E148Q/E148Q | 2 (2.3) |
| L110P/E148Q | 6 (6.9) |
| L110P/E148Q//E148Q | 2 (2.3) |
| L110P/E148Q//R202Q | 1 (1.1) |
| L110P/L110P/E148Q//E148Q | 1 (1.1) |
| E84K/normal | 1 (1.1) |
| E84K/L110P/E148Q | 1 (1.1) |
| Normal | 38 (43.7) |

AOSD adult onset Still's disease

Certain *HLA* alleles have been reported to confer a predisposition to rheumatic diseases [22]. Although no hereditary trend has been reported in AOSD, some studies have reported the associations between HLA-DR and AOSD. Pouchot et al. described a strong association between AOSD and HLA-DR2 [23]. Wouters et al. found an association between *DRB1*04* and AOSD and reported that DR6 (*DRB1*13, *14*) was more frequent in cases with axial joint involvement [24]. Miller et al. reported a frequent association between AOSD and HLA-DR7 [6]. Fujii et al. evaluated the major histocompatibility complex (MHC) class II alleles in 30 Japanese patients with AOSD and reported that *DRB1*15:01* and *DRB1*12:01* were more frequently detected in subjects with chronic articular forms of AOSD than in healthy controls [25]. Additionally, a Korean study showed that patients with AOSD more frequently had *DRB1*12* and **15*, and less frequently had *DRB1*04* than control subjects [26]. However, controversies remain on the association between HLA-DR molecules and AOSD.

Recent studies have provided new clues to the genetic predispositions for developing systemic arthritis. A genome-wide association study of sJIA patients identified a strong association between sJIA and *DRB1*11* [10]. Interestingly, Ombrello et al. raised the new idea that the MHC may act not as an antigen-presenting molecule but rather as a direct activator of MHC class-expressing macrophages or dendritic cells [10]. Our data show that both *DRB1*15:01* and DR5 are associated with AOSD in Japanese patients. *DRB1*15:01* is the HLA allele that was most strongly associated with AOSD in our study, and these results are consistent with those of previous studies in Japanese or Korean patients [25, 26]. Conversely, the *DRB1*09:01* allele had a significantly decreased frequency in patients with AOSD when compared with that in control subjects as reported in multiple sclerosis [27, 28]. However, this negative association of AOSD with the *DRB1*09:01* allele needs to be confirmed in the other ethnic populations because the distribution of HLA alleles is different between Japanese and other ethnic populations. Notably, extensive heterogeneity is observed in the clinical manifestations of AOSD, suggesting that AOSD may actually be a heterogeneous subset of disorders [29]. Our results suggest that *DRB1* alleles may play a role in the occurrence of AOSD; however, it is possible that there are transcriptional changes for other *HLA* loci that are co-inherited with *DRB1*, and these haplotypes may also contribute to the AOSD risk.

It was found that amino acid residues 86 and 98 of the DR β chain were protectively associated with AOSD (Fig. 1). The *DRB1*09:01* allele includes these two amino acid residues, suggesting the predominant protective effects of *DRB1*09:01* on AOSD. Amino acid residues 85, 86, 89, and 90 form the HLA-DR peptide-binding groove for peptide position 1 [30], suggesting the involvement of peptide antigens bound to the specific HLA-DR molecule to prevent AOSD.

MEFV variants are commonly found in the Japanese population [31]. Although the significance of *MEFV* variants is controversial, some studies have suggested that they can influence the phenotypes of inflammatory disorders [32]. Here, we found that the DR5-associated risk for AOSD was not detected in Japanese Patients with AOSD without *MEFV* variants, whereas the DR5-associated risk

Table 5 *HLA-DRB1* allele carrier frequency in the patients with AOSD with or without *MEFV* variants

| | AOSD with <i>MEFV</i> variants | AOSD without <i>MEFV</i> variants | Controls | AOSD with <i>MEFV</i> variants vs. controls | | | | AOSD without <i>MEFV</i> variants vs. controls | | | |
|----------------------------|--------------------------------|-----------------------------------|------------|---|------|----------------------|-------------|--|------|----------------------|-------------|
| | (n = 49) | (n = 38) | (n = 1026) | <i>P</i> | OR | <i>P_c</i> | 95% CI | <i>P</i> | OR | <i>P_c</i> | 95% CI |
| <i>DRB1*15:01</i> | 17 (34.7) | 13 (34.2) | 139 (13.5) | 0.0002 | 3.39 | 0.0068 | (1.83–6.27) | 0.0013 | 3.32 | 0.0388 | (1.66–6.64) |
| DR5(<i>DRB1*11, *12</i>) | 16 (32.7) | 8 (21.1) | 151 (14.7) | 0.0019 | 2.81 | | (1.51–5.23) | 0.2543 | 1.55 | | (0.70–3.43) |

Allele carrier frequencies are shown in parentheses (%). Association was tested by Fisher's exact test using 2 × 2 contingency tables under the dominant model. AOSD adult onset Still's disease, OR odds ratio, CI confidence interval, *P_c* corrected *p* value, NS not significant

Table 6 Comparison of the demographics between patients with AOSD with or without *DRB1*15:01* or *DR5*

| | <i>DRB1*15:01</i> (+) | <i>DRB1*15:01</i> (-) | <i>P</i> | <i>DR5</i> (+) | <i>DR5</i> (-) | <i>P</i> |
|--|-----------------------|-----------------------|----------|-------------------|-------------------|----------|
| Number | 29 | 58 | | 23 | 64 | |
| Female, <i>n</i> (%) | 24 (82.7) | 45 (77.5) | 0.7789 | 20 (86.9) | 49 (77.4) | 0.2912 |
| Age at onset (years) | 46.6 ± 20.3 | 50.6 ± 19.6 | 0.3980 | 50.6 ± 20.5 | 48.1 ± 19.7 | 0.7469 |
| Ferritin (ng/mL) | 12818.5 ± 18292.9 | 10555.5 ± 16284.7 | 0.3657 | 12669.4 ± 16305.9 | 10802.9 ± 17224.9 | 0.3243 |
| CRP (mg/dL) | 11.9 ± 8.2 | 12.7 ± 8.3 | 0.6802 | 12.0 ± 9.2 | 12.6 ± 7.9 | 0.5068 |
| ESR (mm(1 h)) | 59.6 ± 25.3 | 75.4 ± 30.9 | 0.1289 | 67.4 ± 23.0 | 72.5 ± 32.5 | 0.9361 |
| Liver dysfunction, <i>n</i> (%) | 24 (82.7) | 44 (75.8) | 0.4630 | 19 (82.6) | 49 (76.5) | 0.5472 |
| MAS, <i>n</i> (%) | 10 (38.6) | 13 (22.4) | 0.2288 | 10 (43.4) | 13 (20.3) | 0.0307 |
| Initial dose of PSL (mg/day) | 43.8 ± 13.0 | 41.5 ± 11.7 | 0.4379 | 46.1 ± 10.9 | 40.3 ± 12.4 | 0.1184 |
| Steroid pulse, <i>n</i> (%) | 17 (58.6) | 38 (65.5) | 0.4987 | 19 (82.6) | 36 (56.2) | 0.0245 |
| Immunosuppressant, <i>n</i> (%) | 18 (57.6) | 33 (56.8) | 0.6442 | 15 (65.2) | 36 (56.2) | 0.4539 |
| Biologics, <i>n</i> (%) | 10 (38.6) | 16 (27.5) | 0.5077 | 6 (26.0) | 20 (31.2) | 0.6427 |
| Polycyclic systemic type, <i>n</i> (%) | 20 (68.9) | 36 (62.0) | 0.5266 | 18 (78.2) | 38 (59.3) | 0.1048 |
| Monocyclic systemic type, <i>n</i> (%) | 8 (27.5) | 13 (22.4) | 0.5951 | 4 (17.3) | 17 (26.5) | 0.3780 |
| Chronic arthritis type, <i>n</i> (%) | 4 (13.7) | 8 (13.7) | 1.0000 | 2 (8.6) | 10 (15.6) | 0.4085 |
| Relapse, <i>n</i> (%) | 14 (48.2) | 26 (44.8) | 0.7619 | 11 (47.8) | 29 (45.3) | 0.8357 |

Association was tested between patients with adult onset Still's disease (AOSD) with or without *DRB1*15:01* or *DR5* analyzed by the chi-squared test using 2 × 2 contingency tables or the Mann-Whitney *U* test. *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *MAS* macrophage activation syndrome, *PSL* prednisolone

was preserved in Japanese patients with *MEFV* gene variants. These findings suggest a possible interaction between *DRB1* and *MEFV* in AOSD development or in the AOSD disease phenotype. Furthermore, these findings imply that differences between susceptible and non-susceptible *DR5* alleles are complemented by *MEFV* variants in Japanese patients with AOSD, which could be explained by the broad involvement of pyrin, the *MEFV* encoded protein, in the regulation of the inflammasome and inflammatory processes.




Fig. 1 Association between amino acid residues in the DRβ chain and adult onset Still's disease. Differences in amino acid residue carrier frequencies were analyzed by Fisher's exact test using 2 × 2 contingency tables. Corrected *p* (*Pc*) values were calculated by multiplying the *p* value by the number of amino acid residues tested. Predisposing association is indicated by filled circles and protective association by open circles

Rheumatic diseases are likely on the spectrum between autoimmunity and autoinflammation [33]. It was suggested that a pathogenic model in which autoinflammatory processes beget an autoimmune condition, sJIA, is a prototype of AOSD [34]. A genome-wide association study on sJIA identified a strong association between sJIA and *DRB1*11* alleles. *DR5* is a broad-antigen serotype that is further split into HLA-DR11, which includes *DRB1*11:01*, and HLA-DR12 [17]. In our study, patients with *DR5* were more frequently associated with AOSD with macrophage activation syndrome (MAS), which has some similarities to the clinical features of sJIA. These findings are consistent with the reports by Ombrello et al. that demonstrate an association between sJIA and *DRB1*11* alleles [11]. From a pathogenic point of view, most autoinflammatory and autoimmune diseases share a chronic aberrant activation of the immune system, which leads to tissue inflammation and/or damage [35]. In contrast to autoimmune diseases, "autoinflammatory diseases" present with inflammation in the absence of either high-titer autoantibodies or autoreactive T cells. Although the evidence for autoimmunity in AOSD is scant, there are some data that support a role for T cells in its pathogenesis [36]. Additionally, class II HLA molecules have a role in innate immunity and in the regulation of macrophages, including antigen-presenting cells. For example, super-antigen-engaged antigen-presenting cells induce proinflammatory cytokines [37].

There are limitations in our study. Control subjects were younger than the patients. AOSD is a rare disorder

offsetting any potential bias due to development of AOSD later in life by a younger control. Another limitation is that all of our study subjects were Japanese because too few patients from other racial/ethnic backgrounds were available for analysis. Also, the number of patients with AOSD was modest and a larger study would be needed.

Conclusion

Our study provides evidence that *DRB1*15:01* and DR5 confer a risk for AOSD. A protective association between the *DRB1*09:01* allele and AOSD was also observed in this study. Specifically, our data demonstrate that DR5 is associated with AOSD complicated with MAS, in a Japanese population. Additional studies are needed to determine the specific mechanism through which the HLA-DRB1 influences the risk of AOSD.

Additional files

Additional file 1: Figure S1. Primers and polymerase chain reaction conditions. (JPG 171 kb)

Additional file 2: Table S1. HLA-DRB1 allele carrier frequency in the patients with AOSD and age-matched healthy controls (1:2). (PDF 57 kb)

Additional file 3: Table S2. Conditional logistic regression analysis between the protective HLA alleles in AOSD. (PDF 43 kb)

Abbreviations

AOSD: adult onset Still's disease; HLA: human leukocyte antigen; MAS: macrophage-activation syndrome; MHC: Major histocompatibility class; *P_c*: Corrected *p* value; sJIA: systemic juvenile idiopathic arthritis

Acknowledgements

Not applicable.

Funding

The study was supported by the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, AMED.

Availability of data and materials

Not applicable.

Authors' contributions

FH, KE, KY, AK, and KM carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. HF carried out the genetic assays and revised the manuscript. TA, FH, MY, and KM participated in the sequence alignment and drafted the manuscript. MA, YJ, and HK participated in the design of the study, performed the statistical analysis and helped to revise the manuscript. TA, SS, HK, HW, FS, TI, YU, DK, NI, YI, KF, SY, TN, TK, TS, MU, EN, and YU collected the clinical data, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval for this study (number 21003) was provided by the Ethics Committee of Nagasaki Medical Center and written informed consent was obtained from each individual.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan. ²Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan. ³Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation, 2-5-20 Nishinouchi, Koriyama, Fukushima 963-8558, Japan. ⁴Department of Rheumatology Nagaoka Red Cross Hospital, 297-1, Senshu-2, Nagaoka, Niigata 940-2085, Japan. ⁵Department of Rheumatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo 105-8470, Japan. ⁶Department of Rheumatology, Niigata Rheumatic Center, 1-2-8 Honcho, Shibata, Niigata 957-0054, Japan. ⁷Clinical Research Center, NHO Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan. ⁸Department of Rheumatology, Japan Community Health care Organization, Isahaya General Hospital, Eishohigashi-machi 24-1, Isahaya 854-8501, Japan. ⁹Department of Rheumatology, Kurume University Medical Center, Kokubu 155-1 1-2-3, Kurume 734-8551, Japan. ¹⁰Department of Rheumatology, Sakurajyuji Hospital, Miyukibe 1-1-1, Kumamoto 861-4173, Japan. ¹¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto1-7-1, Nagasaki 852-8501, Japan. ¹²Departments of Rheumatology, Sasebo City General Hospital, Hirase 9-3, Sasebo 857-8511, Japan. ¹³Department of Medical Genomics, Life Science Institute, Saga-ken Medical Centre Koseikan, 400 Kasemachi-Nakabaru, Saga 840-8571, Japan. ¹⁴Department of Rheumatology, Sasebo Chuo Hospital, Yamato 15, Sasebo 857-1195, Japan. ¹⁵Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagami-hara National Hospital, 18-1 Sakuradai, Minami-ku, Sagami-hara 252-0392, Japan. ¹⁶Department of Human Genetics, Atomic Bomb Disease Institute, Nagasaki University, Sakamoto 1-12-4, Nagasaki 852-8523, Japan. ¹⁷Department of Gastroenterology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.

Received: 26 March 2017 Accepted: 22 August 2017

Published online: 12 September 2017

References

- Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. *Autoimmun Rev*. 2014;13(7):708–22.
- Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. *Nat Rev Immunol*. 2012;12(8):570–80.
- Rigante D, Vitale A, Lucherini OM, Cantarini L. The hereditary autoinflammatory disorders uncovered. *Autoimmun Rev*. 2014;13(9):892–900.
- Castañeda S, Blanco R, González-Gay MA. Adult-onset Still's disease: Advances in the treatment. *Best Pract Res Clin Rheumatol*. 2016;30(2):222–38.
- Guilpain P, Le Quellec A. About the complexity of adult onset Still's disease... advances still required for its management. *BMC Med*. 2017;15(1):5. <https://doi.org/10.1186/s12916-016-0769-1>.
- Miller ML, Aaron S, Jackson J, et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. *Arthritis Rheum*. 1985;28(2):146–50.
- Heemst J, Huizinga TJ, van der Woude D, Toes RE. Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases: identifying causal amino acid variants? *Curr Opin Rheumatol*. 2015;27(3):256–61.
- Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease. *Semin Arthritis Rheum*. 2006;36(3):144–52.
- Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. *Best Pract Res Clin Rheumatol*. 2009;23(5):655–64.
- Ombrello MJ, Remmers EF, Tachmazidou I, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proc Natl Acad Sci USA*. 2015;112(52):15970–5.
- Nonaka F, Migita K, Jiuchi Y, et al. Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still's disease. *Clin Exp Immunol*. 2015;179(3):392–7.

12. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol*. 1992;19(3):424–30.
13. Cush JJ, Thomas A, et al. Adult-onset Still's disease. *Arthritis Rheum*. 1987;30(2):186–94.
14. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. *Curr Opin Rheumatol*. 2010;22(5):561–6.
15. Ikeda N, Kojima H, Nishikawa M, et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. *Tissue Antigens*. 2015;85(4):252–9.
16. Tilanus MG, Hongming F, van Eggermond MC, et al. An overview of the restriction fragment length polymorphism of the HLA-D region: its application to individual D-, DR- typing by computerized analyses. *Tissue Antigens*. 1986;28(4):218–27.
17. Furukawa H, Oka S, Kawasaki A, et al. Human leukocyte antigen and systemic sclerosis in Japanese: the sign of the four independent protective alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. *PLoS One*. 2016;11(4):e0154255.
18. Migita K, Agematsu K, Yazaki M, et al. Familial Mediterranean fever: genotype-phenotype correlations in Japanese patients. *Medicine (Baltimore)*. 2014;93(3):158–64.
19. Putte LB, Wouters JM. Adult-onset Still's disease. *Baillieres Clin Rheumatol*. 1991;5(2):263–75.
20. Cimaz R. Systemic-onset juvenile idiopathic arthritis. *Autoimmun Rev*. 2016;15(9):931–4.
21. Ombrello MJ. Advances in the genetically complex autoinflammatory diseases. *Semin Immunopathol*. 2015;37(4):403–6.
22. Sparks JA, Costenbader KH. Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases. *Rheum Dis Clin North Am*. 2014;40(4):637–57.
23. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. *Medicine (Baltimore)*. 1991;70(2):118–36.
24. Wouters JM, Reekers P, van de Putte LB. Adult-onset Still's disease. Disease course and HLA associations. *Arthritis Rheum*. 1986;29(3):415–8.
25. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. *Rheumatology (Oxford)*. 2001;40(12):1398–404.
26. Joung CI, Lee HS, Lee SW, et al. Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea. *Clin Exp Rheumatol*. 2003;21(4):489–92.
27. Qiu W, James I, Carroll WM, Mastaglia FL, Kermod AG. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis. *Mult Scler*. 2011;17(4):382–8.
28. Isobe N, Matsushita T, Yamasaki R, et al. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. *Mult Scler*. 2010;16(2):147–55.
29. Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still's disease. *J Autoimmun*. 2014;48-49:34–7.
30. Jardetzky TS, Brown JH, Gorga JC, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. *Nature*. 1994;368:711–8.
31. Sugiura T, Kawaguchi Y, Fujikawa S, et al. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. *Mod Rheumatol*. 2008;18(1):57–9.
32. Rabinovich E, Livneh A, Langevitz P, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. *Ann Rheum Dis*. 2005;64(7):1009–14.
33. Hedrich CM. Shaping the spectrum - from autoinflammation to autoimmunity. *Clin Immunol*. 2016;165:21–8. <https://doi.org/10.1016/j.clim>.
34. Nigrovic PA. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. *Proc Natl Acad Sci USA*. 2015;112(52):15785–6.
35. van Kempen TS, Wenink MH, Leijten EF, Radstake TR, Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. *Nat Rev Rheumatol*. 2015;11(8):483–92.
36. Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. *Rheumatology (Oxford)*. 2010;49(12):2305–12.
37. Krogman A, Tilahun A, David CS, et al. HLA-DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse model. *HLA*. 2017;89(1):20–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

